1. Efficacy of highly bioavailable oral curcumin in asymptomatic or mild COVID-19 patients: a double-blind, randomized, placebo-controlled trial
- Author
-
Atsuhiro Kishimoto, Maki Komiyama, Hiromichi Wada, Noriko Satoh-Asahara, Hajime Yamakage, Yoichi Ajiro, Hiroki Aoyama, Yasuhiro Katsuura, Atsushi Imaizumi, Tadashi Hashimoto, Yoichi Sunagawa, Tatsuya Morimoto, Masashi Kanai, Hideaki Kakeya, and Koji Hasegawa
- Subjects
COVID-19 ,Curcumin ,curcuRouge® ,Clinical trial ,Saturation of percutaneous oxygen ,Body temperature ,Nutritional diseases. Deficiency diseases ,RC620-627 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Introduction Even after the peak of the COVID-19 pandemic, the number of mild cases remains high, requiring continuous control. Curcumin, owing to its anti-inflammatory properties, can suppress vital proliferation and cytokine secretion in animal models. We developed a highly absorbable curcumin, curcuRouge® (cR), which is approximately 100 times more orally bioavailable than conventional curcumin. We evaluated the effect of cR on the inhibition of disease progression in asymptomatic or mildly symptomatic COVID-19 patients. Methods This study evaluated the effect of 7-day oral intake of cR (360 mg twice daily). Patients within 5 days of COVID-19 diagnosis were randomly assigned to a placebo or cR group in a double-blind manner. Results Primary endpoint events [body temperature (BT) ≥ 37.5 °C and saturation of percutaneous oxygen (SpO2)
- Published
- 2024
- Full Text
- View/download PDF